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 We model the glucose–insulin feedback system to study stress hyperglycemia.
 Short acting subcutaneous Lispro and regular insulin injections are simulated.
 The resulting glucose variability after insulin injections is analyzed and compared.
 Regular insulin has the lowest glucose variability proﬁle.
 Lispro is more prone to cause hypoglycemia than regular insulin when the subject is not receiving nutrition.
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a b s t r a c t
Increased glucose variability (GV) is an independent risk factor for mortality in the critically ill;
unfortunately, the optimal insulin therapy that minimizes GV is not known. We simulate the glucose–
insulin feedback system to study how stress hyperglycemia (SH) states, taken to be a non-uniform group
of physiologic disorders with varying insulin resistance (IR) and similar levels of hyperglycemia, respond
to the type and dose of subcutaneous (SQ) insulin. Two groups of 100 virtual patients are studied: those
receiving and those not receiving continuous enteral feeds. Stress hyperglycemia was facilitated by
doubling the gluconeogenesis rate and IR was stepwise varied from a borderline to a high value. Lispro
and regular insulin were simulated with dosages that ranged from 0 to 6 units; the resulting GV was
analyzed after each insulin injection. The numerical model used consists of a set of non-linear
differential equations with two time delays and ﬁve adjustable parameters. The results show that
regular insulin decreased GV in both patient groups and rarely caused hypoglycemia. With continuous
enteral feeds and borderline to mild IR, Lispro showed minimal effect on GV; however, rebound
hyperglycemia that increased GV occurred when the IR was moderate to high. Without a nutritional
source, Lispro worsened GV through frequent hypoglycemia episodes as the injection dose increased.
The inferior performance of Lispro is a result of its rapid absorption proﬁle; half of its duration of action
is similar to the glucose ultradian period. Clinical trials are needed to examine whether these numerical
results represent the glucose–insulin dynamics that occur in intensive care units, and if such dynamics
are present, their clinical effects should be evaluated.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
In 2001, a study by Van den Berghe changed the intensive care
unit (ICU) practice of hyperglycemia management around the
world (Van den Berghe et al., 2001). Traditionally, efforts were
made to keep blood glucose concentrations below 200 mg/dl;
however, Van den Berghe showed that tight glycemic control
(TGC) between 80 and 110 mg/dl reduces a patient's morbidity
and mortality. The improved outcomes led to an increase in the
number of ICUs that adopted a TGC policy (Lowery and Badawi,
2013). The initial optimism, however, was followed by concerns
regarding the universal applicability of this treatment, as new
trials, including one from the original Van den Berghe group (Van
den Berghe et al., 2006), did not corroborate the initial ﬁndings.
Several trials and meta-analyses that followed demonstrated a
signiﬁcant risk associated with TGC resulting from hypoglycemia
and increased GV (Wiener et al., 2008; Finfer et al., 2009;
Griesdale et al., 2009). Currently, the glycemic control pendulum
has swung back toward a higher initial glucose concentration of
150 mg/dl before insulin therapy is initiated (Jacobi et al., 2012).
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Insulin infusions are generally recommended to treat hyperglyce-
mia in the ICU; however, subcutaneous insulin injections are still
used by some providers in critical care because of their ease of use
for the nursing staff and the requirement for relatively infrequent
blood draws from the patient.
One recent landmark randomized controlled trial that reported
increased mortality with TGC in ICU patients was the Normogly-
cemia in Intensive Care Evaluation-Survival Using Glucose Algo-
rithm Regulation trial (Finfer et al., 2009). This large, prospective,
study of adult medical and surgical ICU patients showed that
aggressive glucose control may actually increase overall mortality
rates, although two subgroups seemed to show a beneﬁt: patients
receiving steroids and trauma patients. Deﬁning higher glucose
concentrations as acceptable, however, is not necessarily much
safer since hyperglycemia, hypoglycemia, and increased GV have
similar associated mortality risks (Badawi et al., 2012). In fact,
increased GV is itself an independent risk factor associated with
hospital mortality in the critically ill (Egi et al., 2006; Ali et al.,
2008; Dossett et al., 2008; Krinsley, 2008; Hermanides et al.,
2010). The mechanism is not well understood, but in vitro studies
have shown that acute ﬂuctuations of glucose can induce endothe-
lial cell damage and apoptosis; this may be one reason by which
GV confers worse outcomes (Risso et al., 2001; Quagliaro et al.,
2003).
A critical reading of the published literature concerning insulin
therapies in intensive care indicates that different patient popula-
tions have variable responses to the same insulin treatment (Jacobi
et al., 2012); thus, there may not be a single best insulin protocol
for the treatment of SH. Future design of clinical trials may then be
aided by an improved understanding of how a non-uniform group
of physiologic disorders, each producing similar levels of hyper-
glycemia, would respond to exogenous insulin. One technique that
could help provide such insight is to mathematically model the
glucose–insulin axis, simulate various SQ insulin therapies, and
examine the resultant GV. One modeling approach explicitly
incorporates two time delays that exist in the glucose–insulin
system. One time delay is due to processes inside the pancreas:
β-cells release insulin due to stimulation from glucose. This
physiological action requires a certain time for the newly synthe-
sized insulin, or “remote insulin”, to cross the endothelial barrier
before it can be released. The other time delay represents the
effect of insulin on hepatic glucose production; although insulin
regulates the liver in a direct fashion, its effect occurs over several
minutes. These two time delays are an important reason why the
glucose–insulin feedback system is able to sustain ultradian
oscillations (Li et al., 2006; Li and Kuang, 2007).
The models may be used to qualitatively compare SQ insulin
therapies for the treatment of SH in an ICU setting. Two commonly
used SQ insulin products are Lispro and regular insulin. Lispro, an
insulin analogue, has a quick 5–15 min onset of action and peaks
in 30–90 min with an effective duration of only 4–6 h (Hirsch,
2005a). This type of insulin was designed to treat diabetics
enjoying a food bolus. The resulting peak in endogenous insulin
levels after a meal has a similar time duration to Lispro; hence,
Lispro tends to lower glucose levels in diabetics more effectively
than regular insulin. Another advantage of Lispro's short duration
of action is that “insulin stacking” (a second insulin injection being
given while insulin absorption continues from the previous injec-
tion) is thought to be minimized. Regular insulin, in contrast, has
an onset of action of about 30 min and peaks in 2–3 h with a
longer effective duration of 6–8 h (Hirsch, 2005a).
To our knowledge, there has been no clinical or numerical
study that compares SQ Lispro and regular insulin therapy for SH
in the critically ill; using numerical simulation to examine such a
comparison is the main focus of this paper. The paper is organized
as follows: Section 2 contains a description of the mathematical
model and the numerical methods used. Stress hyperglycemia is
commonly a combination of increased gluconeogenesis and IR;
insulin resistance is a common adaptive responsive seen in several
patient groups, such as post abdominal surgical patients (Thorell
et al., 1994), trauma patients (Black et al., 1982), and those
suffering from sepsis (Gump et al., 1974; Andersen et al., 2004).
The numerical model consists of a set of non-linear differential
equations with two time delays; these equations have been used
to study insulin therapy for diabetics with variable IR. Stress
hyperglycemia is produced by doubling the amplitude of the
function representing glucose production by the liver and adding
the effects of varying levels of IR. Functions representing SQ Lispro
and regular insulin injections are used to perturb the system at a
glucose concentration maximum; the resulting GV is then ana-
lyzed. Glucose variability is deﬁned as the average difference
between adjacent glucose local maximum (or peaks) and local
minimum (or troughs) across each ultradian oscillation. The
simulation results are presented in Section 3, which is followed
by a discussion in Section 4. A conclusion in Section 5 ﬁnishes
the paper.
2. Glucose–insulin axis model and numerical methods
In the last few decades, several mathematical models have
been proposed and studied with the aim of better understanding
the dynamics of the glucose–insulin axis so that safer and more
effective insulin administration practices could be developed to
treat diabetes mellitus (Li et al., 2006; Li and Kuang, 2007; Bennett
and Gourley, 2004a,b; Della Man et al., 2002; Doran et al., 2005;
Engelborghs et al., 2001; Mukhopadhyay et al., 2004; Palumbo
et al., 2007; Sturis et al., 1991; Tolic et al., 2000; Wang and
Li, 2007; Wilinska et al., 2005; Wang et al., 2009; Chen and Tsai,
2010; Wu et al., 2011). The ﬁeld has a rich history surveyed in
reviews (Makroglou et al., 2006, 2011; Palumbo et al., 2013). These
methods can be modiﬁed to model the effects of SQ insulin when
used for SH in the ICU. The types of insulin therapies studied in
this paper are restricted to those that would administer SQ
injections of either Lispro or regular insulin; the term SQ will
henceforth be dropped as an insulin injection descriptor.
The particular model used here (extensively studied in Chen
and Tsai, 2010) deﬁnes G(t) and I(t) to be the glucose and insulin
concentration at time tZ0, respectively. Mass conservation
implies
∂tGðtÞ ¼ fGpðtÞGuðtÞg : glucose productionglucose utilization;
ð2:1aÞ
∂t IðtÞ ¼ fIpðtÞ IcðtÞg : insulin production insulin clearance;
ð2:1bÞ
where
GpðtÞ ¼ GinðtÞþ f 5ðIðtτ2ÞÞ  f 6ðGðtÞÞ; ð2:2aÞ
GuðtÞ ¼ f 2ðGðtÞÞþβ  f 3ðGðtÞÞ  f 4ðIðtÞÞþ f 7ðGðtÞ330Þ; ð2:2bÞ
IpðtÞ ¼ IinðtÞþα f 1ðGðtτ1ÞÞ; ð2:2cÞ
IcðtÞ ¼ diIðtÞ: ð2:2dÞ
The functions fi, where i¼ 1-7, describe the body's glucose
production and utilization, as well as insulin production and
clearance; Gin(t) in Eq. (2.2a) denotes glucose absorption from
either enteral nutrition or an intravenous source. Insulin absorp-
tion from an exogenous source is represented by IinðtÞ in Eq. (2.2d).
Each of the fi functions will be discussed next; they have been
determined from work that deﬁnes some of the key aspects of
glucose and insulin metabolism in function form. References to the
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original physiological experiments may be found in Tolic et al.
(2000).
In vivo, insulin production and release only occurs in the
pancreatic β cells and is approximated by f 1ðGðtτ1ÞÞ in
Eq. (2.2c). The production of insulin occurs predominately in
response to elevated glucose concentrations although free fatty
acids and most amino acids can also stimulate the β cells. The
process of insulin secretion from the pancreas involves a series of
complex steps, ﬁrst being the entry of glucose into the islet cell. Due
to this chain of events, a time delay, here referred to as τ1, is required
for the pancreas to respond to elevated glucose levels in a delayed
fashion. Exogenous insulin from clinical therapy is captured by IinðtÞ.
The liver and kidney are the primary sites of portal insulin
degradation and peripheral insulin clearance, respectively. Insulin
not cleared by the liver and kidney is ultimately removed by other
tissues, such as muscle and adipose cells. The insulin degradation is a
regulated process involving insulin binding to its receptor, internaliza-
tion into a cell, and then degradation. Experiments have shown that
the relationship of insulin degradation is proportional to its concen-
tration; one may then write the insulin clearance rate as diIðtÞ
(Eq. (2.2d)), where di is a positive constant. (However, more accurate
models of insulin clearance have been developed, Wang et al., 2009.)
There are two sources for glucose: dietary or intravenous
sources, denoted by GinðtÞZ0, and glucose production from the
liver. When plasma glucose levels drop, the pancreatic β cells slow
or stop insulin production and release. The pancreatic α cells,
however, then release glucagon, a hormone that stimulates liver
gluconeogenesis (or glucose production). The function f 5ðIðtτ2ÞÞ
in Eq. (2.2a) describes gluconeogenesis and has a time delay τ2
that allows for the time lag needed for glucagon's secretion and
action upon the liver to produce and release glucose. The function
f 6ðGðtÞÞ in Eq. (2.2a) captures the dynamic of hyperglycemia being
a powerful inhibitor of hepatic glucose production.
Glucose utilization also consists of two parts, namely, insulin-
independent and insulin-dependent utilization. The insulin-
independent glucose tissue consumers are mainly brain and nerve
cells, and their glucose consumption is denoted in Eq. (2.2b) by
f 2ðGðtÞÞ, indicating its dependency on glucose levels alone. The
function f 7ðGðtÞÞ in Eq. (2.2b) describes glucose uptake by splanch-
nic tissues (liver and gastrointestinal tract) during hyperglycemic
events. Glucose utilization by the muscle and fat cells depends on
both insulin and glucose concentration. The glucose-dependent
term is the function f 3ðGðtÞÞ and f 4ðIðtÞÞ is the insulin-dependent
term, such that the total glucose utilization from these tissues is
the product f 3ðGðtÞÞf 4ðIðtÞÞ, see Eq. (2.2b).
The explicit forms of functions f1 through f7 are
f 1ðGðtτ1ÞÞ ¼
Rc
1þexpððc1ðGðtτ1Þ=VgÞÞð1=e1ÞÞ
; ð2:3aÞ
f 2ðGðtÞÞ ¼ Ub  ½1expððGðtÞ=c2VgÞ; ð2:3bÞ
f 3ðGðtÞÞ ¼
GðtÞ
c3Vg
; ð2:3cÞ
f 4ðIðtÞÞ ¼Uoþ
UcUo
1þexpðκ log ððIðtÞ=c4Þð1=VcÞþð1=EtcÞÞÞ
; ð2:3dÞ
f 5ðIðtτ2ÞÞ ¼
Rg
1þexpðe1ððIðtτ2Þ=VpÞc5ÞÞ
; ð2:3eÞ
f 6ðGðtÞÞ ¼
1
expðγððGðtÞ=c3VgÞc6ÞÞ
; ð2:3fÞ
f 7ðGðtÞ330Þ ¼ Sbþ
ScSb
1þexpðδðððGðtÞ330Þ=c3VgÞc7ÞÞ
; ð2:3gÞ
and the experimentally determined constants associated with
each equation are listed in Table 1.
Eqs. (2.1a) and (2.1b) are solved by employing a fourth-order
Runge–Kutta scheme with a ﬁxed one-second time step, appro-
priately modiﬁed to account for the two time delays τ1 and τ2
(Lakshmanan and Senthilkumar, 2010). The system of equations to
be solved are of the form ∂tx¼ f ðt; xðtÞ; xðtτÞÞ and we use the
notation ϕnτ=h  xðtnτÞ to denote the value of the system τ time
units ago. It is assumed for convenience that hm¼ τ, for some
integer m. The Runge–Kutta scheme then evaluates
k1 ¼ hf ðtn; xn;ϕn τ=hÞ; ð2:4aÞ
k2 ¼ hf tnþ
h
2
; xnþk12 ;
ðϕn τ=hþϕnþ1 τ=hÞ
2
 !
; ð2:4bÞ
k3 ¼ hf tnþ
h
2
; xnþ
k2
2
;
ðϕn τ=hþϕnþ1 τ=hÞ
2
 !
; ð2:4cÞ
k4 ¼ hf ðtnþh; xnþk3;ϕnþ1τ=hÞ; ð2:4dÞ
where ϕnþ1þ τ=h is the system τ units before xnþ1; and
xnþ1 ¼ xnþðh=6Þðk1þ2k2þ2k3þk4Þ. Such a scheme is used to
solve Eqs. (2.1a) and (2.1b) with the initial conditions
Ið0Þ ¼ Io40, Gð0Þ ¼ Go40, GðtÞ ¼ Go for each tA ½τ1;0 and
IðtÞ ¼ Io for tA ½τ2;0. The equations of motion are then inte-
grated for 1500 min to remove any artifact from the artiﬁcial initial
conditions before a simulated insulin injection is given.
The model deﬁned by Eqs. (2.3a) (through 2.3g) has ﬁve
adjustable parameters: α; β; τ1; τ2 and di; their deﬁnitions deter-
mine the respective dynamics of the oscillatory behavior of the
glucose–insulin axis for normal and diabetic subjects. An extensive
examination of the model showed that when the parameters were
chosen to reproduce the glucose–insulin dynamics of normal
subjects and type I/type II diabetics, the corresponding parameter
values could be used to identify the underlying pathophysiology of
the subject (Chen and Tsai, 2010).
Other studies have used similar models to show that it is possible
to mimic pancreatic insulin secretion by an exogenous source com-
posed of a short-acting insulin, Lispro, and a long-acting insulin,
Glargine (Wang and Li, 2007). These numerical results demonstrated
that for diabetic patients who are eating normally, Lispro more
effectively controls glucose proﬁles as compared to regular insulin; a
result consistent with clinical trials (Recasens et al., 2003; Anderson
et al., 1997). Currently, an insulin pump is the most advanced method
of insulin administration for type I diabetics. It is hoped that with
further reﬁnement, such models can form a solid foundation for an
artiﬁcial pancreas (Huang et al., 2012).
In the aforementioned numerical studies, SH was not examined. In
the hospital setting, a combination of factors affect the development of
SH (Dungan et al., 2009). The mechanisms for this disorder vary with
Table 1
Parameters and associated values for the functions f1 through f7.
Parameters Values Units Parameters Values Units
Vg 10 l E 0.2 l/min
Vp 3 l e1 300 mg/l
Vc 11 l c1 2000 mg/l
Ub 72 mg/min c2 144 mg/l
Uc 940 mg/min c3 1000 mg/l
Uo 40 mg/min c4 80 mU/l
κ 1.77 c5 26 mU/l
tc 100 min Rg 180 mg/min
Rc 210 mU/min c6 2 mg/l
γ 5 Sc 140 mg/min
Sb 20 mg/min c7 2 mU/l
δ 2.4
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the patients' underlying glucose tolerance, type and severity of disease,
and the stage of illness; there is a highly complex interplay of counter-
regulatory hormones involving catecholamines and cortisol (Barth
et al., 2007; Andrews and Walker, 1999). High hepatic output of
glucose, especially through gluconeogensis, seems to be the most
important contributor to SH (Jeevanandam et al., 1990; McGuinness
et al., 1993). Excessive glucagon is the primary mediator of gluconeo-
gensis (Lang et al., 1989), although epinephrine (McGuinness et al.,
1997) and cortisol (Fujiwara et al., 1996) also contribute. The simula-
tion of stress hyperglycemia will then involve increased rates of
gluconeogenesis.
Gluconeogenesis, or glucose production by the liver, is described in
Eq. (2.3e) by f 5ðIðtτ2ÞÞ, and is primarily regulated by glucagon (Lang
et al., 1989). The form of f 5ðIðtτ2ÞÞ has been derived from experi-
mental data obtained from normal subjects (see Tolic et al., 2000 and
references therein). The way in which f 5ðIðtτ2ÞÞ is modiﬁed so SH
results was motivated by the previous work in which the functions
that describe different aspects of the glucose–insulin axis for normal
subjects are changed to produce the dynamics seen in type I and
type II diabetes. In particular, the dynamics that capture type I diabetes
are produced by decreasing the amplitude of f 1ðGðtτ1ÞÞ, which
represents insulin production by the pancreatic islet cells, via
f 1ðGðtτ1ÞÞ-α f 1ðGðtτ1ÞÞ, where αo1. Similarly, type II dia-
betics are simulated by the change f 3ðGðtÞÞ  f 4ðIðtÞÞ-β  f 3ðGðtÞÞ
f 4ðIðtÞÞ, with βo1, as f 3ðGðtÞÞ  f 4ðIðtÞÞ are the terms which describe
the insulin-dependent glucose utilization by fat and other cells.
We propose to simulate SH by increasing the rate of gluconeo-
genesis through the modiﬁcation: f 5ðIðtτ2ÞÞ-ϝf 5ðIðtτ2ÞÞ,
where the constant ϝ will be changed from unity (representing
normal subjects) to 2 (representing a physiologic stressed subject
with doubled hepatic glucose production). Note, it was assumed
that the shape of f 5ðIðtτ2ÞÞ does not change, perhaps reasonable
as it has been shown that the shapes of f1, f2, f4, and f5 are more
important than their functional form when modeling normal
subjects (Keener and Sneyd, 2010). In addition, stress hyperglyce-
mia frequently involves elevated levels of IR; it is a common
adaptive responsive seen in many patient groups, such as post
abdominal surgical patients (Thorell et al., 1994), trauma patients
(Black et al., 1982), and those suffering from sepsis (Gump et al.,
1974; Andersen et al., 2004). Some argue that increased IR allows
more glucose to become available for the injured tissues to utilize.
We thus include IR in our model by allowing β in Eq. (2.2b) to
assume the values 0.8–0.5, in 0.1 intervals, to represent borderline,
mild, moderate, and severe IR, respectively.
A constant external source of glucose, Gin in Eq. (2.2a), will
represent the virtual patient's nutrition.
Injections of Lispro will be modeled with the piecewise func-
tion ILisðtÞ (Wang and Li, 2007):
ILisðtÞ ¼
0:25 for 0rto5;
0:25þ 1þ t30
305
 
for 5rto30;
0:25þ 1 t30
12030
 
for 30rto120;
0:25 for 120rtr240:
8>>>><
>>>>:
ð2:5Þ
Similarly, IRegðtÞ will represent a regular insulin injection (Wang
and Li, 2007):
IRegðtÞ ¼
0:25 for 0rto30;
0:25þ 1þt120
90
 
for 30rto120;
0:25þ 10:5 t120
120
 
for 120rto240;
0:25þ0:5 1t240
240
 
for 240rtr480;
8>>>>><
>>>>>:
ð2:6Þ
where the time t in both ILisðtÞ and IRegðtÞ is measured in minutes.
The functions ILisðtÞ and IRegðtÞ may be thought of as time
dependent perturbations to the glucose–insulin axis, each with
their own associated time scales of 240 and 480 min, respectively.
Their resulting effects are expected to decrease mean glucose
values for a duration similar to their time scales; however, it is not
clear how GV will be affected when the patient is not receiving
nutrition in a quasi-periodic, bolus form.
The model reproduces the expected G(t) and I(t) behavior for a
normal subject; the ultradian oscillations in glucose and insulin
concentrations, for the parameter values α¼ 1; β¼ 1, τ1 ¼ 15 min,
τ2 ¼ 5 min, and di¼0.06 (values found in normal subjects, Chen
and Tsai, 2010), are presented in Figs. 1 and 2, respectively. The
mean glucose is 92.5 mg/dl and GV is 19.4 mg/dl. Note that the
glucose concentration is seen to oscillate between 84 mg/dl and
103 mg/d with a period of 110 min, all within the expected normal
range. Similarly, insulin concentrations oscillate between
26 μU=ml and 41 μU=ml; however, the insulin peaks are noted
to “lag” behind the glucose concentration peaks by approximately
16 min, consistent with τ2. The units of G(t) and I(t) in the
functions f1 through f7 are in mg and mU, respectively. They are
ﬁrst converted to mg/dl and μU=ml before G(t) and I(t) are
presented in ﬁgure form. GV was calculated as the averaged
difference between adjacent peaks and troughs across each ultra-
dian oscillation with units mg/dl; note, there is no single accepted
deﬁnition of GV (Siegelaar et al., 2010).
3. Simulation results
The glucose–insulin system is studied in detail for SH states
where the rate of gluconeogenesis is doubled and the level of IR is
varied. This is accomplished by setting ϝ¼ 2 and varying IR
involves assigning β the values 0.8, 0.7, 0.6, and 0.5. The IR of a
normal subject ranges between 0.8 and 1.0; borderline, mild,
moderate, and severe are descriptors used for β¼ 0:8, 0.7, 0.6,
and 0.5, respectively. The parameters di¼0.17 and τ2 ¼ 15 min
deﬁne the rate of insulin clearance and pancreatic time delay; τ1,
or hepatic delay, is ﬁxed so that the baseline glucose maximums
are in the range of 150–160 mg/dl. The descriptor baseline refers
to simulations where no insulin injection was given. The values of
τ1 ¼ 6; 7; 10 and 13 min accomplish this task for β¼ 0:8; 0:7; 0:6,
and 0.5, respectively. Note that all parameter values, except for β
and ϝ, are within a range found in normal subjects (Chen and Tsai,
2010).
Before an insulin injection is simulated, the equations of
motions are integrated for 1500 min to remove artifacts in G(t)
and I(t) due to the artiﬁcial initial conditions. All insulin injections
Fig. 1. G(t), glucose vs time, for a normal subject. Parameters for simulation: α¼ 1,
β¼ 1; τ1 ¼ 15 min, τ2 ¼ 5 min, and di¼0.06. Mean glucose is 92.5 mg/dl, GV is
19.4 mg/dl and the period is 110 min.
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are given at a G(t) maximum; and ﬁgures containing G(t) vs time
data have t¼0 as the time of injection. The local minimum of G(t)
are referred to as troughs; and the local G(t) maximum, or peaks,
are counted from the ﬁrst trough. This syntax is used for all G(t)
graph descriptions. Insulin injections are simulated using ILisðtÞ
and IRegðtÞ in Eqs. (2.5) and (2.6). The resulting perturbation of G(t)
is then analyzed in terms of hypoglycemia and GV. The functions
ILisðtÞ and IRegðtÞ are normalized so that the total number of Lispro
and regular insulin units per injection is the same when the
simulation model parameters are equal; total insulin doses range
between 0 (baseline simulations) and 6 units.
3.1. Simulations with Gin ¼ 1:35 mg=dl min
In the ﬁrst simulation series (100 injections per insulin type),
the virtual subject receives a continuous source of glucose (either
enteral or intravenous) with Gin ¼ 1:35 mg=dl min in Eq. (2.2a).
Fig. 3 contains the change in GV vs injection-dose curves for a
series of Lispro injections. Graph deﬂections below y¼0 imply a
decrease in GV; since the baseline simulations have zero units of
insulin injected, the change in GV for each of the curves is zero at
the origin. The ﬁgure shows that when borderline or mild IR is
present, GV does not signiﬁcantly depend on the Lispro dose as it
remains fairly constant with dose increases. When moderate IR is
present; however, GV increases beyond the baseline value after
approximately 5 U. Worsening GV is also noted with severe IR and
the baseline GV is exceeded with less insulin delivered, about 3 U.
Fig. 4 contains the change in GV vs injection-dose data for
regular insulin. The ﬁgure demonstrates that GV monotonically
decreases for each curve in the series, all roughly in a linear
fashion. It should be noted that there were no episodes of
hypoglycemia, deﬁned as a GðtÞo60 mg=dl, noted for any of the
Lispro or regular insulin injections simulated. The minimum and
maximum glucose concentrations across the entire series studied
were approximately 90 mg/dl and 160 mg/dl, respectively.
To understand the reason why Lispro and regular insulin have
different patterns in GV, G(t) vs time curves are analyzed. Two
simulations are presented: one simulation has borderline IR and
the other severe IR. In both simulations, 4 units of insulin are
injected. Fig. 5 contains the G(t) vs time data for borderline IR
(β¼ 0:8 and τ1 ¼ 6). The baseline series is shown with diminished
font to serve as a guide to the eye so that an estimation of the
changes to G(t) from the insulin injections can be made; the
baseline ultradian oscillations in glucose concentrations range
between 156 mg/dl and 113 mg/dl with a period of 109 min. The
ﬁgure demonstrates that the effects of Lispro have a duration
approximately half that of regular insulin, consistent with ILisðtÞ
and IRegðtÞ. Lispro produces a glucose minimum of nearly 90 mg/dl at
the ﬁrst trough and its effects are no longer present after 300 min,
except for a rightward shift in the peaks of G(t) along the time axis.
The second G(t) peak is the smallest, with a value of 138 mg/dl. The
curve representing regular insulin has a glucose minimum at the
second trough of 107 mg/dl; the glucose concentration oscillations
return to their initial amplitude after 500 min, consistent with IRegðtÞ
(the peaks of G(t) have again shifted to the right).
An inspection of Fig. 5 shows why the GV is decreased for regular
insulin and is essentially unchanged for Lispro. The reason GV is
minimally affected by Lispro, despite the fact that the average glucose
value is decreased, is due to the fact that Lispro is short acting and
produces a smaller G(t) minimum just after the injection. Recall the
deﬁnition of GV used: the average distance between adjacent peaks
Fig. 2. I(t), Insulin vs time, for a normal subject. Parameters for simulation:
α¼ 1; β¼ 1, τ1 ¼ 15 min, τ2 ¼ 5 min, and di¼0.06. Mean insulin is 32:6 μU=ml
and the period is 110 min; note, I(t) lags behind G(t) by 16 min.
Fig. 3. The change in GV vs the total number of Lispro units injected. Variable IR
values (β¼ 0:8; 0:7; 0:6 and 0.5) are denoted by borderline, mild, moderate, and
severe; Gin ¼ 1:35 mg=dl min. Graph deﬂections below y¼0 imply a decrease in GV.
Fig. 4. The change in GV vs the total number of regular insulin units injected.
Variable IR values (β¼ 0:8; 0:7; 0:6 and 0.5) are denoted by borderline, mild,
moderate, and severe; Gin ¼ 1:35 mg=dl min. Graph deﬂections below y¼0 imply
a decrease in GV.
Fig. 5. G(t) vs time for borderline IR (β¼ 0:8Þ, τ2 ¼ 6 and Gin ¼ 1:35 mg=dl min; 4 U
of Lispro and regular insulin were injected at t¼0. The corresponding baseline
simulation is also plotted.
R.J. Strilka et al. / Journal of Theoretical Biology 356 (2014) 192–200196
and troughs of G(t). Lispro produces a fairly deep ﬁrst trough (just after
the injection) which increases GV. The distance from the ﬁrst trough to
the second peak, however, is similar to the distance between the
baseline peaks and troughs; this does not signiﬁcantly effect GV. Also,
the distance between the second trough and peak, as well as between
the second peak and the third trough, has been decreased; this does
lower GV. However, since the effects of Lispro have worn off by the
third peak, GV remains essentially unchanged when all these distances
(between adjacent peaks and troughs) are averaged.
The glucose–insulin dynamics change signiﬁcantly when IR is
severe, as shown in Fig. 6 (β¼ 0:5 and τ1 ¼ 13). As in Fig. 5, 4 U of
insulin are injected and the plots are G(t) vs time. The baseline
ultradian oscillations have an amplitude of 153 mg/dl, a trough of
119 mg/dl, and a period of 111 min. The Lispro injection produces a
G(t) minimum of 103 mg/dl at the ﬁrst trough and its effects are
again not present after 300 min, except for a similar G(t) peak shift
to the right. The important difference between the Lispro injec-
tions shown in Figs. 5 and 6 (borderline vs severe IR) is that
rebound hyperglycemia is now present. Note that the ﬁrst G(t)
peak in the Lispro curve exceeds that of the baseline. The rebound
hyperglycemia, after the ﬁrst trough, explains in part the increased
GV shown in Fig. 3. The other contribution to the GV increase is the
fairly deep ﬁrst trough. When all the distances between adjacent
glucose peaks and troughs are averaged, GV is increased.
The regular insulin curve in Fig. 6 is also different from its
corresponding graph in Fig. 5: the ﬁrst peak value is 14 mg/dl less
with severe IR (127 mg/dl vs 141 md/dl). That is, regular insulin
causes a greater G(t) peak suppression as IR worsens. Also of note,
the amplitude is suppressed for an additional 250 min beyond the
duration of IRegðtÞ; the G(t) dynamics do not return to baseline
until 750 min. This suggests that “insulin stacking” may also occur
for dynamical reasons and may not simply be related to the
duration of drug absorption. The general observation is that the
glucose–insulin system appears more sensitive to insulin pertur-
bation as the IR is increased.
An inspection of Figs. 5 and 6 shows that no hypoglycemia
episodes are present. The G(t) vs time curves in the Gin ¼
1:35 mg=dl min series are qualitatively similar; and therefore, no
other data is presented.
3.2. Simulations with Gin ¼ 0 mg=dl min
In the second set of simulations presented (100 injections per
insulin type), the external glucose source has been removed and
Gin ¼ 0 mg=dl min. The remaining parameters are identical to
those in Section 3.1, thus the two sets of simulations may be
compared. The baseline G(t) vs time graphs are not shown as the
glucose–insulin dynamics are simpler; each baseline curve has an
approximate ultradian oscillation trough of 80 mg/dl, a peak of
150 mg/dl, and a period of 110 min.
Fig. 7 contains the change in GV vs injection-dose curves for
Lispro; it shows that for each Lispro injection, the change in GV is
roughly independent of the IR value. Also, GV is seen to increase
with injection doses greater than 2.5 U. The change in GV is different
when regular insulin is injected, as shown in Fig. 8: self-similar
curves show GV slowly decreasing as the regular insulin dose is
increased, but again the curves appear independent of the IR value.
To appreciate why Lispro and regular insulin produce different
GV behavior, plots of G(t) vs time are presented for two simulations;
model parameters are the same as those used in Figs. 5 and 6,
except now the tube feeds are absent and Gin ¼ 0 mg=dl min. Fig. 9
contains G(t) for borderline IR (β¼ 0:8, τ1 ¼ 6) with 4 U of insulin
injected. Of note, the Lispro injection causes a G(t) ﬁrst trough value
of approximately 40 mg/dl, an episode of severe hypoglycemia; the
second trough of the regular insulin series is nearly 60 mg/dl
(a borderline hypoglycemic event). Fig. 10 shows G(t) for severe IR
(β¼ 0:5, τ1 ¼ 13) and 4 U insulin injected. The Lispro ﬁrst trough
value is again 40 mg/dl while the regular insulin second trough is
70 mg/dl. Similar to Section 3.1, the Lispro effects are not present
after 300 min; however, the regular insulin effects for both simula-
tions are absent well before 500 min.
Note that there are no episodes of rebound hyperglycemia and the
increase in GV from Lispro is due almost solely to the severe
hypoglycemia produced. The other G(t) vs time curves in the
Gin ¼ 0 mg=dl min series are qualitatively similar and no simulations
contain rebound hyperglycemia; therefore, no other G(t) data is
presented. To clarify the extent of hypoglycemia for each insulin type,
Fig. 6. G(t) vs time for severe IR (β¼ 0:5Þ; τ2 ¼ 13 and Gin ¼ 1:35 mg=dl min; 4 U of
Lispro and regular insulin were injected at t¼0. The corresponding baseline
simulation is also plotted.
Fig. 7. The change in GV vs the total number of Lispro units injected. Variable IR
values (β¼ 0:8; 0:7; 0:6 and 0.5) are denoted by borderline, mild, moderate, and
severe; Gin ¼ 0 mg=dl min. Graph deﬂections above y¼0 imply an increase in GV.
Fig. 8. The change in GV vs the total number of regular insulin units injected.
Variable IR values (β¼ 0:8; 0:7; 0:6 and 0.5) are denoted by borderline, mild,
moderate, and severe; Gin ¼ 0 mg=dl min. Graph deﬂections below y¼0 imply a
decrease in GV.
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Figs. 11 and 12 plot the change in G(t) minima vs injection-dose for
Lispro and regular insulin, respectively. The curves show that all Lispro
injections decrease the G(t) minima at a similar rate as the dose is
increased; hypoglycemia is quickly reached by about 2.25 U. The G(t)
minima vs injection-dose curves for regular insulin also decrease with
self-similar rates; however, there are only a few simulations that
produce hypoglycemia (G(t) minimum r60 mg=dl), namely high
insulin dose with severe IR.
4. Discussion
Stress hyperglycemia and the resultant GV after SQ Lispro and
regular insulin therapy have been extensively studied numerically.
Glucose variability is clinically important because its presence is
associated with negative patient outcomes in critical care medicine
(Egi et al., 2006; Ali et al., 2008; Dossett et al., 2008; Krinsley, 2008;
Hermanides et al., 2010). The reasonwhy GV confers a poorer outcome
is likely multi-factorial. For example, GV is more likely to produce
apoptosis than sustained hyperglycemia (Risso et al., 2001; Quagliaro
et al., 2003). These effects may be mediated via wide variations in
osmolarity that in turn could affect cellular and organ function (Otto
et al., 2008). Oxidative stress, also produced in greater levels during
glucose ﬂuctuations than by sustained hyperglycemia (Schiekofer
et al., 2003), may be one of the unifying mechanisms underpinning
the vasoconstriction, microvascular thrombosis, and inﬂammation
associated with hyperglycemia and glycemic variability (Monnier et
al., 2006; Hirsch, 2005b). In a recent retrospective study involving
surgical critical care patients, it was reported that the highest mortality
rate was noted when GV and hyperglycemia were both present; and
that GV was the more important predictor of outcome (Hermanides et
al., 2010). Furthermore, another study noted that GV was associated
with increased mortality, but the mean blood glucose level was not
associated with increased mortality in patients with sepsis (Dossett
et al., 2008). Thus, some argue that glucose management protocols
should focus on GV, rather than glucose concentration, as the
treatment target because it has the stronger link to patient outcome.
Guidelines for the treatment of hyperglycemia in the ICU
setting recommend an insulin infusion. As hyperglycemia devel-
ops, however, some critical care providers ﬁrst turn towards a
sliding scale insulin (SSI) protocol; and if the SSI treatment does
not control the glucose levels in a satisfactory manner, an insulin
infusion is started. Sliding scale insulin therapies instruct nurses to
provide an SQ insulin injection whose dose is based on glucose
levels derived from the patient every 4–6 h. Lispro and regular
insulin are both used in the ICU setting, although there are no
studies that deﬁne the frequency of their use. Furthermore, we
know of no study that compares the performance of Lispro and
regular insulin in the ICU in terms of their respective GVs.
These extensive numerical simulations of the glucose–insulin
feedback system, with focus on the system's response to SQ insulin
injections, allow insight into the effects of SSI therapies when used for
SH. The model parameters chosen produce SH with various degrees of
IR. Each simulation, or virtual patient, was assumed to be receiving
either a constant, or absent, external source of glucose and represents
a spectrum of pathophysiologic states found in critical care. Only the
qualitative differences of the insulin injection effects on G(t) will be
discussed, as speciﬁc differences would be an inappropriate applica-
tion of the model.
A summary of the qualitative differences of the GV is listed in
Table 2. When an external source of glucose is present, regular insulin
was shown to reduce GV in a linear fashion as the injection dose was
Fig. 9. G(t) vs time for borderline IR (β¼ 0:5Þ; τ2 ¼ 6 and Gin ¼ 0 mg=dl min; 4 U
Lispro and regular insulin were injected at t¼0.
Fig. 10. G(t) vs time for severe IR (β¼ 0:5Þ; τ2 ¼ 13 and Gin ¼ 0 mg=dl min; 4 U of
Lispro and regular insulin were injected at t¼0.
Fig. 11. The change in glucose minima vs the total number of Lispro units injected.
Variable IR values (β¼ 0:8; 0:7; 0:6 and 0.5) are denoted by borderline, mild,
moderate, and severe; Gin ¼ 0 mg=dl min. Graph deﬂections below y¼0 imply
a decrease in glucose minima.
Fig. 12. The change in glucose minima vs the total number of regular insulin units
injected. Variable IR values (β¼ 0:8; 0:7; 0:6 and 0.5) are denoted by borderline,
mild, moderate, and severe; Gin ¼ 0 mg=dl min. Graph deﬂections below y¼0 imply
a decrease in glucose minima.
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increased; no hypoglycemia events were noted. This pattern was
unchanged when IR was varied from borderline to severe. The
behavior of G(t) after a Lispro injection was quite different; GV was
essentially unaffected regardless of the insulin dosage used, provided
that the IR was borderline or mild. Lispro, however, increased GV as
the injection dose was increased when the IR was moderate or severe.
These trends are captured in Table 2, where the term low IR denotes
borderline or mild IR, high IR denotes moderate or severe IR, ⇆
implies minimum change, and ↑↓ are increase and decrease,
respectively.
The different G(t) behavior after a Lispro and regular insulin
injection may be understood in terms of the duration of each type
of insulin injection (Lispro 240min and regular insulin 480min) as
compared to the period of the baseline ultradian oscillations (approxi-
mately 110 min). The Lispro injection increases to its absorption
maximum in 120min, or approximately in half of the baseline
ultradian oscillation period; it then decreases to zero within the same
time span. The action of a regular insulin injection, on the other hand,
is spread over approximately ﬁve ultradian oscillation periods. In other
words, Lispro, with its more rapid onset and cessation, occurs over a
timeframe that does not allow the glucose–insulin feedback system to
return to a baseline state without ﬁrst overshooting and worsening
hyperglycemia and GV; IR makes the glucose–insulin system more
sensitive to short insulin perturbations of the SQ type. It is worth
noting that the increased GV may go unrecognized since it occurs
within a timeframe before the next blood glucose check dictated by a
typical SSI protocol – a glucose check every 4–6 h. Table 2 also shows
that when the external glucose source is removed, the GV pattern is
the same – Lispro increases GV while regular insulin decreases GV;
however, the mechanism is different than previously discussed. In this
case, it was shown that Lispro was prone to cause hypoglycemia, and
this increased the glucose variability.
The trends of GðtÞmin, or minimum G(t) values, are captured in
Table 3; here ↓ marks GðtÞmin values that are signiﬁcantly below
baseline levels, while avoiding hypoglycemia, + identiﬁes hypo-
glycemic events (GðtÞr60 mg=dl), and ⇆ implies minimal change.
When Gin ¼ 0 mg=dl min, Lispro is prone to create hypoglycemia,
and regular insulin produces a lower GðtÞmin that avoids hypogly-
cemia unless severe IR is combined with larger injection doses.
The reason why Lispro produces a greater GðtÞmin value, as
compared to regular insulin, is again explained by its duration of
action being similar to the baseline ultradian period. Table 3 also
captures that neither insulin type reduces GðtÞmin signiﬁcantly
when a continuous source of glucose is present.
5. Conclusion
Stress hyperglycemia with variable IR may be simulated using a
two time-delay non-linear model of the glucose–insulin axis. The
model allows for a qualitative study of GV and hypoglycemia
following SQ injections of Lispro and regular insulin; in addition,
the dynamical response of the glucose–insulin system to insulin
can be studied for various values of IR.
Simulations suggest that depending on the level of IR present,
SH states respond differently to the type and dose of SQ insulin
used; these states represent a spectrum of pathophysiologic
diseases. Furthermore, the dynamics of the glucose–insulin sys-
tems appears more sensitive to insulin perturbation as the IR
increases. This suggests that in disease states with evolving and
worsening IR, insulin therapies that are dynamic and use relatively
smaller adjustments in the exogenous insulin dose, as the IR
worsens, may be of beneﬁt (Evans et al., 2011).
The simulated SH states before injection yielded ultradian
glucose oscillations with approximate peaks of 160 mg/dl and
periods of 110 min. Regular insulin decreased GV in both patient
groups and rarely caused hypoglycemia. With continuous enteral
feeds and low IR, Lispro showed minimal effect on GV; however,
rebound hyperglycemia that increased GV occurred when the IR
was high. Without a nutritional source, Lispro worsened GV
through frequent hypoglycemia episodes as the injection dose
increased. The increased GV and hypoglycemia observed with
Lispro would not be evident if glucose monitoring occurred every
four hours, typical time frames used in sliding scale subcutaneous
insulin therapies.
The inferior performance of Lispro, in terms of GV and
hypoglycemia, is a result of its rapid absorption proﬁle; half of
its duration of action is similar to the glucose ultradian period and
that allows for a dynamic similar to resonance in mechanical
systems. In patients who are not receiving bolus feeds, Lispro
should not be used to treat SH, as hypoglycemia may result.
Regular insulin, however, performed well and consistently
decreased GV without causing hypoglycemia.
Clinical trials are needed to examine whether these numerical
results represent the glucose–insulin dynamics that occur in
intensive care units, and if such dynamics are present, their clinical
effects should be evaluated.
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